Oncology and Advanced Solid Tumors
Bicycletx Limited focuses on advanced malignancies across multiple solid-tumor settings, with research centred on cancers that express specific tumor-associated targets.
- Advanced solid tumors
- Metastatic cancer
- Tumor-targeted oncology
Its clinical portfolio includes studies in advanced breast cancer, non-small cell lung cancer, and other difficult-to-treat malignant diseases.
EphA2-Directed Cancer Research
The sponsor investigates cancers associated with EphA2 expression, reflecting a strong interest in tumors defined by this surface marker.
- EphA2-expressing tumors
- Urothelial cancer
- Head and neck cancer
Research activity extends across ovarian cancer, triple-negative breast cancer, and gastric and upper gastrointestinal cancer in the context of EphA2-linked disease biology.
Nectin-4-Expressing Malignancies
Bicycletx Limited also studies Nectin-4-driven cancers, with work spanning tumors identified by NECTIN4 amplification or Nectin-4 expression.
- NECTIN4-amplified tumors
- Nectin-4-expressing advanced malignancies
- Locally advanced or metastatic urothelial cancer
This area includes research in urothelial carcinoma, advanced breast cancer, and non-small cell lung cancer.
Immuno-Oncology and Combination Cancer Treatment
The sponsor’s trial landscape includes interest in immuno-oncology, particularly combinations involving pembrolizumab and other established anticancer therapies.
- Checkpoint inhibitor combinations
- Metastatic urothelial carcinoma
- Solid tumor treatment combinations
These studies address both monotherapy and combination approaches in advanced cancer populations.
